We have just launched NXtec D008 DMD – the first dedicated neuromuscular assay to be added to our digitalMLPA™ catalogue – designed for the reliable detection of CNVs in the DMD gene. Read more.
Our digitalMLPA™ portfolio is about to receive an update with the upcoming launch of NXtec D008 DMD – our first dedicated neuromuscular digitalMLPA assay. Read more.
The external test phase for digitalMLPA assay NXtec D011 Cardiac Panel is about to start, and we are looking for test labs. Read more.
We have just launched NXtec D008 DMD – the first dedicated neuromuscular assay to be added to our digitalMLPA™ catalogue – designed for the reliable detection of CNVs in the DMD gene. Read more.
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! The first batch of flagship products are already available on the market under the new IVDR, well in advance of the transition period deadline. Read more.
D007 Acute Lymphoblastic Leukemia was recognized as a valuable tool for enhanced molecular testing of adult ALL cases in work shown recently at a scientific congress. Read more.
Join our mailing list to receive the latest information about our products, technologies and website.